Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is well-positioned for future success, as demonstrated by its strong financial results and guidance, especially in the crucial Sterigenics segment. The company's new CEO, Alton Shader, brings a fresh perspective and continuity to the team, and has already implemented strategic planning processes to drive growth and manage capital allocation. The company has also successfully de-risked legal issues surrounding its Sterigenics business, showing its commitment to responsible and ethical operations. These factors, combined with a steady track record of execution, make Sotera Health a strong investment opportunity.

Bears say

Sotera Health is facing ongoing legal challenges and risks related to its operations, with a recent settlement in the New Mexico public nuisance case but ongoing trials set for 2027. The company's recent revenue growth in the Sterigenics segment may be short-lived, as management points to favorable comp schedules and specific customer conversions rather than sustained demand across the customer base. Additionally, the company's reliance on outsourced terminal sterilization and irradiation services could face increased competition or regulatory scrutiny in the future, potentially impacting its revenue and profitability.

Sotera Health (SHC) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 7 analysts, Sotera Health (SHC) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.